+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rare Biomarkers Specimen Collection and Stabilization Market By Type, By Product, By Application: Global Opportunity Analysis and Industry Forecast, 2021-2031

  • PDF Icon

    Report

  • 356 Pages
  • October 2022
  • Region: Global
  • Allied Market Research
  • ID: 5725066
The global rare biomarketrs specimen collection and stabilization market was valued at $23,270.04 million in 2021, and is projected to reach $54,145.59 million by 2031, registering a CAGR of 8.7% from 2022 to 2031. Biomarketr is a measurable indicator of some biological state or condition. It is usually used in the measurement and evaluation of blood, urine, and soft tissues. Biomarketrs focus on monitoring vital parameters such as heart rate and accelerometer data. In rare biomarketr specimen collection, the rare disease-causing microorganisms are identified by evaluating blood and other parts of body. These samples are stabilized by using isolation kits, reagents, and other equipment for further study. Molecular biomarketrs, cellular biomarketrs, and imaging biomarketrs are the three different types of biomarketrs.

However, a biomarketr can lessen the burden of the clinical trial process by providing information about the safety and efficacy of treatments before the collection of definitive clinical data, which provides the opportunity for mid‐course re‐appraisal, and even interruption if the intervention being investigated is revealed as potentially harmful to participants.

The key factors that drive the growth of market are rise in prevalence of chronic & genetic diseases, increase in incidence of rare diseases such as cystic fibrosis, muscular dystrophy, & spina bifida; and rise in geriatric population. For instance, in May, 2022 Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marketd in vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This single test kit, launched across Europe, assesses multiple tumor genes and biomarketrs to reveal the specific molecular profile of a patient's cancer.

Moreover, increased R&D activities for the launch of approved novel drugs on rare diseases, favorable government reimbursement policies for rare biomarketrs, surge in investment in the modern healthcare facility sector, and rise in demand for accurate chronic disease diagnosis are anticipated to fuel the market growth.

However, stringent government regulations and high cost associated with the development of rare biomarketrs specimen and standardization hamper the market growth. Conversely, emerging healthcare market in developing countries, increase in applications of rare biomarketr specimens in pharmacogenomics, and surge in the risk of pandemic & rare genetic diseases are expected to provide lucrative opportunity for the growth of market during the forecast period.

The rare biomarketrs specimen collection and stabilization market is segmented on the basis of type, product, application, and region. By type, the market is categorized into circulating cell free DNA, circulating tumor cells, and exosomes vesicles. By product, the market is classified into isolation kits & reagents, blood collection tubes, and systems. By application, the market is fragmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and other. By application, the oncology segment is further sub-classified into research and diagnostics. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the rare biomarketr’s specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The rare biomarketrs specimen collection and stabilization market is mainly driven by rise in prevalence of chronic & genetic diseases, increase in the healthcare expenditure, surge in number of approved rare biomarketr isolation kits for both clinical and research use are anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region which propels the growth of the market.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, rise in investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring have provided lucrative growth opportunities to players, which is further expected contribute to the growth of the market.

The key players that operate in the rare biomarketrs specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc and Siemens AG.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarketrs specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarketrs specimen collection and stabilization market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the rare biomarketrs specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global rare biomarketrs specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Circulating Cell Free DNA (ccfDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes Vesicles

By Product

  • Isolation Kits and Reagent
  • Blood Collection Tubes
  • Systems

By Application

  • Transcriptomics
  • Pharmacogenomics
  • Transplant Rejection
  • Population Screening
  • Others
  • Oncology
  • Type
  • Research
  • Diagnostics
  • Cardiovascular Diseases
  • NIPT

By Region

  • North America
  • U. S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA

Key Market Players

  • Agilent Technologies Inc
  • F Hoffman La Roche
  • Merck Kgaa
  • Bio Rad Laboratories
  • Thermofischer Scientific Inc
  • Qiagen
  • Perkin Elmer
  • Charles River Laboratories International, Inc.
  • Siemens Healthineers
  • Eurofins Scientific, Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Circulating Cell Free DNA (ccfDNA)
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Circulating Tumor Cells (CTCs)
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Exosomes Vesicles
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Isolation Kits and Reagent
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Blood Collection Tubes
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Systems
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oncology
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
6.2.4.1 Research Market size and forecast, by region
6.2.4.2 Diagnostics Market size and forecast, by region
6.3 Cardiovascular Diseases
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 NIPT
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Transcriptomics
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
6.6 Pharmacogenomics
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market analysis by country
6.7 Transplant Rejection
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market analysis by country
6.8 Population Screening
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market analysis by country
6.9 Others
6.9.1 Key market trends, growth factors and opportunities
6.9.2 Market size and forecast, by region
6.9.3 Market analysis by country

CHAPTER 7: RARE BIOMARKERS SPECIMEN COLLECTION AND STABILIZATION MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Product
7.2.4 North America Market size and forecast, by Application
7.2.4.1 North America Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Application
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Application
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Application
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Product
7.3.4 Europe Market size and forecast, by Application
7.3.4.1 Europe Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Application
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Application
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Application
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Application
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Application
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Application
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Product
7.4.4 Asia-Pacific Market size and forecast, by Application
7.4.4.1 Asia-Pacific Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Application
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Application
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Application
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Application
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Application
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Application
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Product
7.5.4 LAMEA Market size and forecast, by Application
7.5.4.1 LAMEA Oncology Rare Biomarkers Specimen Collection and Stabilization Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Application
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Application
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Application
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Application

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Agilent Technologies Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 F Hoffman La Roche
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck Kgaa
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bio Rad Laboratories
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Thermofischer Scientific Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Qiagen
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Perkin Elmer
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Charles River Laboratories International, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Siemens Healthineers
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Eurofins Scientific, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Rare Biomarkers Specimen Collection and Stabilization Market,' the Rare Biomarkers Specimen Collection And Stabilization Market Size was valued at $23.3 billion in 2021, and is estimated to reach $54.2 billion by 2031, growing at a CAGR of 8.7% from 2022 to 2031.

Biomarkers are the measures used to perform a clinical assessment such as blood pressure or cholesterol level and are used to monitor and predict health states in individuals or across populations so that appropriate therapeutic intervention can be planned. Biomarkers may be used alone or in combination to assess the health or disease state of an individual.

A wide range of biomarkers are used. Every biological system (for example, the cardiovascular system, metabolic system, or the immune system) has its own specific biomarkers. Many of these biomarkers are relatively easy to measure and form part of routine medical examinations. For example, a general health check may include assessment of blood pressure, heart rate, cholesterol, and fasting glucose levels. Body measurements such as weight, body mass index (BMI), and waist-to-hip ratio are routinely used for assessing conditions such as obesity and metabolic disorders.

The principles of biomarkers in disease have been applied to the detection, screening, diagnosis, treatment, and monitoring of cancer. Traditionally, anti-cancer drugs were agents that killed both cancer cells and healthy cells. However, more targeted therapies have now been developed that can be directed to kill cancer cells only, while sparing healthy cells.

The key factors that drive the growth of the market are the rise in the prevalence of cancer and chronic diseases. Moreover, an increase in the geriatric population, a surge in the adoption of advanced healthcare services, and a rise in investments in R&D by biopharmaceutical companies propel the growth of the rare biomarker specimen collection and stabilization market. For instance, Hereditary Angioedema (HAE) is an autosomal dominant genetic disorder that affects 1 in 50,000 people. It is caused in most cases by a pathogenic variant in SERPING1, encoding the C1-inhibitor (C1-INH), leading to deficiency or dysfunction of C1-INH (HAE types 1 and 2 [HAE-1/2], respectively). Thus, in order to guide the therapeutic management in HAE, it can be of great benefit to utilizing biomarkers, i.e., biological indicators of disease state, as it may be possible to personalize the treatment according to the biomarker status. Therefore, the rise in the adoption of biomarkers to treat genetic disorders propels the Rare Biomarkers Specimen Collection And Stabilization Market Growth in the forecast period.

Furthermore, an increase in the number of studies in the area of rare biomarker specimens and a surge in usage of clinical utilities for drug development purposes are the major factors that drive the growth of the market.

However, the high cost of the biomarker’s development and the lack of skilled personnel are the major barriers for the growth of the market. Emerging economies such as India, China, Mexico, and Brazil are anticipated to create new opportunities during the forecast period due to an increase in applications of rare biomarker specimens in pharmacogenomics and disease diagnosis.

On the basis of type, the rare biomarkers specimen collection and stabilization market is segmented into circulating cell-free DNA, circulating tumor cells, and exosome vesicles. In 2021, the circulating cell-free DNA segment accounted for the largest Rare Biomarkers Specimen Collection And Stabilization Market Share. The dominance of this segment can be attributed to the increasing adoption of NIPT in detecting chromosomal anomalies in the fetus and as it is a very promising tumor biomarker for cancer diagnosis & monitoring, prognosis assessment, and personalized medication guidance.

On the basis of product, the Rare Biomarkers Specimen Collection And Stabilization Industry is categorized into isolation kits & reagents, blood collection tubes, and systems. The isolation kits & reagents segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to rise in prevalence of cancer & rare genetic disorder and the increase in investment for exploring the utility of CTCs in diagnosis, prognosis, and treatment monitoring are the Rare Biomarkers Specimen Collection And Stabilization Market Trends that propel the growth of the market in upcoming years.

By application the market is classified into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. The oncology segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to surge in prevalence of cancer cases, which has increased the demand for rare biomarkers and advancement in technology coupled with an increased interest in personalized medication.

North America accounted for a majority of the rare biomarker’s specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period owing to the high adoption of technologically advanced imaging systems, increase in the healthcare expenditure, and presence of major key players in the region & the strategies they adopt for their product development.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period. The market growth in the Asia-Pacific is supplemented by the rise in demand for minimal invasive therapies, healthcare reforms, highly populated countries along with high birth rate, and surge in prevalence of chronic diseases. In addition, the increasing patient awareness and presence of high unmet needs in the developing nations, especially in countries such as India and China, are expected to further drive the market growth.

The key players that operate in the rare biomarkers specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc, and Siemens AG.

Key findings of the study

By type, the circulating cell free DNA segment was the highest contributor to the market in 2021.

By product, the isolation kits & reagents segment was the highest contributor in 2021.

By application, the oncology dominated the market in 2021 and is expected to continue this trend during the forecast period.

By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • Agilent Technologies Inc.
  • F Hoffman La Roche
  • Merck KGaA
  • Bio Rad Laboratories
  • Thermofischer Scientific Inc.
  • Qiagen
  • Perkin Elmer
  • Charles River Laboratories International, Inc.
  • Siemens Healthineers
  • Eurofins Scientific, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information